Search

Displaying results 2611 - 2620 of 7687 in total
  1. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF

  2. Drug

    SYNB1020

    go.drugbank.com/drugs/DB17667
    Investigational

    SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc. … discontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study.

  3. Drug

    Tetraethylammonium

    go.drugbank.com/drugs/DB08837
    Investigational

    Structurally, tetraethylammonium is positively charged due to its central quaternary ammonium. … Tetraethylammonium is an experimental drug with no approved indication or marketed formulation.

  4. Drug

    SBT-100

    go.drugbank.com/drugs/DB17215
    Experimental

    It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136] … SBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody (sdAb).

  5. Drug

    Cat dander extract

    go.drugbank.com/drugs/DB13904
    Approved

    Cat dander extract can be used in immunotherapy in individuals who cannot avoid exposure to cat allergens to initiate hyposensitization. … An allergic reaction to cats is induced by the presence of antigen-specific IgE antibodies that are bound to specific receptors on mast cells and basophils.

  6. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the FDA … The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.

  7. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. … [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.

  8. Drug

    Pasireotide

    go.drugbank.com/drugs/DB06663
    ApprovedInvestigational

    Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

    Synonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
  9. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    [A263506] It was subsequently approved by the FDA in March 2024.[L50386] … [A263501,L50411] Danicopan is a small molecule complement factor D inhibitor that selectively blocks the alternative pathway, thereby working to address extravascular hemolysis when used in conjunction

    Categories: Complement Factor D Inhibitor
  10. Drug

    Alglucerase

    go.drugbank.com/drugs/DB00088
    ApprovedWithdrawn

    Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market. … Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD.